(VIANEWS) – Krystal Biotech (KRYS), Riot Blockchain (RIOT), TG Therapeutics (TGTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Krystal Biotech (KRYS)
781.5% sales growth and 8.87% return on equity
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Krystal Biotech has a trailing twelve months EPS of $2.19.
PE Ratio
Krystal Biotech has a trailing twelve months price to earnings ratio of 81.66. Meaning, the purchaser of the share is investing $81.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.87%.
Sales Growth
Krystal Biotech’s sales growth for the next quarter is 781.5%.
2. Riot Blockchain (RIOT)
95.2% sales growth and 8.06% return on equity
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.06%.
Sales Growth
Riot Blockchain’s sales growth is 3.8% for the ongoing quarter and 95.2% for the next.
Volume
Today’s last reported volume for Riot Blockchain is 16893100 which is 30.91% below its average volume of 24453700.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 17.6% and 64%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.3%, now sitting on 286.74M for the twelve trailing months.
3. TG Therapeutics (TGTX)
67.5% sales growth and 43.93% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.3.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 52.7. Meaning, the purchaser of the share is investing $52.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.93%.
Yearly Top and Bottom Value
TG Therapeutics’s stock is valued at $15.81 at 16:22 EST, way below its 52-week high of $29.32 and way higher than its 52-week low of $6.46.
Moving Average
TG Therapeutics’s value is above its 50-day moving average of $15.57 and way higher than its 200-day moving average of $13.63.
Volume
Today’s last reported volume for TG Therapeutics is 2504130 which is 20.35% below its average volume of 3143930.
4. Horace Mann Educators Corporation (HMN)
9.2% sales growth and 5.52% return on equity
Horace Mann Educators Corporation, together with its subsidiaries, operates as an insurance holding company in the United States. It operates in three segments: Property & Casualty, Life & Retirement, and Supplemental & Group Benefits. The company underwrites and markets personal lines of property and casualty insurance, including personal lines auto and property insurance products; supplemental insurance products, which include cancer, heart, hospital, supplemental disability, and accident coverages; retirement products, such as tax-qualified fixed and variable annuities; and life insurance products comprising whole life and term, as well as indexed universal life insurance products. It also offers student loan solutions, including online student loan management accounts for educators. The company markets its products through its sales force of full-time exclusive agents to K-12 teachers, administrators, and other employees of public schools and their families. Horace Mann Educators Corporation was founded in 1945 and is headquartered in Springfield, Illinois.
Earnings Per Share
As for profitability, Horace Mann Educators Corporation has a trailing twelve months EPS of $1.57.
PE Ratio
Horace Mann Educators Corporation has a trailing twelve months price to earnings ratio of 21.73. Meaning, the purchaser of the share is investing $21.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.52%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 13, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 4.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.1%, now sitting on 1.52B for the twelve trailing months.
5. Virtus Investment Partners (VRTS)
6.9% sales growth and 14.9% return on equity
Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs quantitative analysis to make its investments. It benchmarks the performance of its portfolios against the S&P 500 Index. The firm conducts in-house research to make its investments. Virtus Investment Partners, Inc. was founded in 1988 and is based in Hartford, Connecticut.
Earnings Per Share
As for profitability, Virtus Investment Partners has a trailing twelve months EPS of $16.6.
PE Ratio
Virtus Investment Partners has a trailing twelve months price to earnings ratio of 13.37. Meaning, the purchaser of the share is investing $13.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.9%.
Yearly Top and Bottom Value
Virtus Investment Partners’s stock is valued at $221.98 at 16:22 EST, way under its 52-week high of $263.39 and way above its 52-week low of $168.78.
